Impact of timing of trastuzumab initiation on long-term outcome of patients with early-stage HER2-positive breast cancer: the "one thousand HER2 patients" project.

Br J Cancer · 2018 · PMC6070916 · PMID 29773838

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

In our study, the timing of trastuzumab was a significant determinant of outcome, with a highly significant difference in DFS and OS for those receiving trastuzumab within and those beyond 12 weeks.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.